Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia

Landiolol, an ultra-short-acting β1-selective blocker, is more effective in controlling heart rate compared with digoxin in patients with atrial tachyarrhythmias and left ventricular dysfunction. However, the effect of atrial tachyarrhythmia type on the effectiveness of landiolol remains unknown. He...

Full description

Bibliographic Details
Published in:	Medicina
Main Authors:	Kengo Ayabe, Tomoyoshi Komiyama, Hiroyuki Takekawa, Honsa Kang, Yasuaki Tsumagari, Miwa Ito, Keiichi Ashikaga, Yoshisato Shibata
Format:	Article
Language:	English
Published:	MDPI AG 2024-10-01
Subjects:	landiolol HFpEF HFmrEF HFrEF β-blocker
Online Access:	https://www.mdpi.com/1648-9144/60/11/1782

Similar Items

A Comprehensive Profile of Heart Failure Patients Across Ejection Fraction Subtypes: Insights from a Single-Center Retrospective Cohort Study
by: Austėja Kaunaitė, et al.
Published: (2025-08-01)

Heart failure: an update from the last years and a look at the near future
by: Mauro Riccardi, et al.
Published: (2022-12-01)

Atrial Fibrillation, Heart Failure Phenotypes, and Mortality Risk in the Nationwide START Registry: A Propensity Score Matching Analysis
by: Danilo Menichelli, et al.
Published: (2025-06-01)

Correction: Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-07-01)

EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design
by: Matthias Paul, et al.
Published: (2025-08-01)

Phenotyping patients with chronic obstructive pulmonary disease and heart failure
by: Peter Moritz Becher, et al.
Published: (2025-04-01)

Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-05-01)

Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study
by: Kathleen Connolly, et al.
Published: (2024-08-01)

D‐dimer and outcomes in hospitalized heart failure patients across the ejection fraction phenotypes
by: Liyan Huang, et al.
Published: (2022-10-01)

Anemia in Heart Failure: Diagnostic Insights and Management Patterns Across Ejection Fraction Phenotypes
by: Otilia Țica, et al.
Published: (2025-08-01)

Heart failure outcomes by left ventricular ejection fraction in a contemporary region‐wide patient cohort
by: Johan Sundström, et al.
Published: (2024-06-01)

Role of ejection fraction in patients at risk for advanced heart failure: insights from the HELP‐HF registry
by: Matteo Pagnesi, et al.
Published: (2024-02-01)

Sacubitril/Valsartan vs ACE Inhibitors or ARBs
by: Endurance Evbayekha, MD, et al.
Published: (2025-03-01)

Benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis
by: Verena Tscholl, et al.
Published: (2021-08-01)

Sex differences in mortality and hospitalization in heart failure with preserved and mid-range ejection fraction: a systematic review and meta-analysis of cohort studies
by: You Deng, et al.
Published: (2024-01-01)

Hospitalized patients and stimulant use-associated heart failure: importance of ejection fraction and related risk factors
by: Akshat Agrawal, et al.
Published: (2025-07-01)

Comparison of Patients with Reduced and Mildly Reduced Left Ventricular Ejection Fraction: Intermediate Data from the FAR NHL Registry
by: Alžběta Trčková, et al.
Published: (2022-10-01)

The Prognostic Value of Anemia in Patients with Preserved, Mildly Reduced and Recovered Ejection Fraction
by: Anita Pintér, et al.
Published: (2022-02-01)

A higher mortality in men compared to women with heart failure in primary care and ejection fraction equal to or more than 40%
by: Björn Eriksson, et al.
Published: (2024-12-01)

Tyrosine to threonine ratio was related to heart failure with reduced or mildly reduced ejection fraction
by: Qing Fen Zhou, et al.
Published: (2024-06-01)

Glycosphingolipids in Cardiovascular Disease: Insights from Molecular Mechanisms and Heart Failure Models
by: Sarah Huang, et al.
Published: (2024-10-01)

Small Heart Size and Premature Death in 366,484 Individuals With Normal Ejection Fraction
by: Stephanie J. Rowe, BBiomed, MD, et al.
Published: (2025-01-01)

Identifying plasma proteomic signatures from health to heart failure, across the ejection fraction spectrum
by: Karolina Andrzejczyk, et al.
Published: (2024-06-01)

Hydrogen Sulfide as a Potential Therapy for Heart Failure—Past, Present, and Future
by: Kyle B. LaPenna, et al.
Published: (2021-03-01)

The use of sacubitril/valsartan in different forms of heart failure
by: Mohammad Abumayyaleh, et al.
Published: (2025-06-01)

Intravenous iron in heart failure: still no prognostic impact, but questions remain
by: Ibrahim El-Battrawy, et al.
Published: (2025-08-01)

Association between blood eosinophil levels and prognosis in critically ill patients with different heart failure phenotypes
by: Chengjian Guan, et al.
Published: (2025-02-01)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
by: Norman Mangner, et al.
Published: (2023-10-01)

The value of echocardiographic measurement of epicardial adipose tissue in heart failure patients
by: Gijs vanWoerden, et al.
Published: (2022-04-01)

Multi‐microRNA diagnostic panel for heart failure with preserved ejection fraction in preclinical and clinical settings
by: Reza Parvan, et al.
Published: (2025-08-01)

Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy
by: Natasha L. Patel‐Murray, et al.
Published: (2024-07-01)

Real‐world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction
by: Jenni Huusko, et al.
Published: (2020-06-01)

Large Animal Models of Heart Failure: Reduced vs. Preserved Ejection Fraction
by: Christopher J. Charles, et al.
Published: (2020-10-01)

Therapeutic implications of statins in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction: a review of current literature [version 1; peer review: 2 approved]
by: Chanavuth Kanitsoraphan, et al.
Published: (2021-01-01)

Exercise Mode in Heart Failure: A Systematic Review and Meta-Analysis
by: Jamie Edwards, et al.
Published: (2023-01-01)

A Review of Contemporary and Future Pharmacotherapy for Chronic Heart Failure in Children
by: Bibhuti B. Das
Published: (2024-07-01)

Artificial Intelligence-Guided Neuromodulation in Heart Failure with Preserved and Reduced Ejection Fraction: Mechanisms, Evidence, and Future Directions
by: Rabiah Aslam Ansari, et al.
Published: (2025-08-01)

Association of Long‐Term Body Mass Index Variability With the Development of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction Across Patterns of Weight Change
by: Zeshui Yu, et al.
Published: (2025-09-01)

Can Plasma ADAMTS13 Differentiate Patients With Pulmonary Arterial Hypertension From Other Forms of Pulmonary Hypertension and Dyspnea Control PatientsTake-Home Points
by: Kriss Kania, MD, et al.
Published: (2025-09-01)

Prognostic and predictive microRNA panels for heart failure patients with reduced or preserved ejection fraction: a meta-analysis of Kaplan–Meier-based individual patient data
by: Reza Parvan, et al.
Published: (2025-07-01)